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407 melanoma patients who underwent vitamin D testing were identified. 102 patients were tested at primary melanoma diagnosis; 289 at follow-up and 16 at recurrence.
Median age was 66 years (21-90 years). Female to male distribution was equal (153:154). patients aged ≥65 years were more likely to be VitD-(p<0.000, P<0.001) -We found no seasonal variation in the vitamin D levels in all groups.
Our audit has revealed a significant trend towards increasing vitamin D deficiency in melanoma patients in long-term follow-up, though initial incidence in melanoma patients at diagnosis was also high (46%). Older patients and those with higher-risk primaries were more likely to be VitD-and should be specifically targeted. Primary tumours in the VitD-cohort were associated with higher mitotic rate and ulceration; both characteristics have well-known-associations with lower survival probability (7).
VitD-is common in the UK melanoma patient and is associated with risk of melanoma relapse (2). Currently, evidence is lacking regarding direct therapeutic value of vitamin D supplementation in melanoma patients and the need for further research in this area has been highlighted (8) . 
